Page last updated: 2024-12-06

adenylyl imidodiphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Adenylyl imidodiphosphate (AMP-PNP) is a non-hydrolyzable analog of ATP. It is synthesized by reacting adenosine 5'-monophosphate (AMP) with imidotriphosphate. AMP-PNP acts as a competitive inhibitor of ATP hydrolysis by ATPases, including protein kinases. It is often used in biochemical studies to investigate the role of ATP hydrolysis in enzyme mechanisms and cellular processes. AMP-PNP can bind to ATP-binding sites on proteins, but it cannot be hydrolyzed, allowing researchers to study the initial binding and conformational changes that occur upon ATP binding without the subsequent hydrolysis step. AMP-PNP is also used to study the role of ATP in signal transduction pathways and to probe the structure and function of ATP-binding sites on proteins. It is a valuable tool for understanding the role of ATP in a variety of cellular processes.'

Adenylyl Imidodiphosphate: 5'-Adenylic acid, monoanhydride with imidodiphosphoric acid. An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID33113
CHEMBL ID1230989
CHEBI ID47785
SCHEMBL ID612075
MeSH IDM0000416

Synonyms (48)

Synonym
CHEMBL1230989
gtpl2456
5'-adenylic acid, monoanhydride with imidodiphosphoric acid (8ci,9ci)
gamma-imino-atp
atp[beta,gamma-nh]
beta,gamma-imido-atp
adenosine beta,gamma-imidotriphosphate
beta,gamma-imino-atp
amp-pnp
adenosine 5'-(beta,gamma-iminotriphosphate)
adenyl imidodiphosphate
adenosine, 5'-o-[hydroxy[[hydroxy(phosphonoamino)phosphinyl]oxy]phosphinyl]-
beta,gamma-imino-adenosine 5'-triphosphate
imidodiphosphoric acid, monoanhydride with 5'-adenylic acid (8ci)
adenylyl imidodiphosphate
adenosine 5'-(beta,gamma-imidotriphosphate)
5'-adenylyl (beta,gamma-imidodiphosphate)
25612-73-1
adenylyl beta,gamma-imidodiphosphate
5'-adenylyl imidodiphosphate
app(nh)p
1BXR
2A29
CHEBI:47785 ,
o(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine
5'-o-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine
adenyl-5'-yl imidodiphosphate
amppnp
formycin a 5'-(betagamma-imido)triphosphate
3B5Y
5'-adenylic acid, monoanhydride with imidodiphosphoric acid
amp.p[nh]p
bdbm18134
({[({[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}amino)phosphonic acid
5-adenylyl imidodiphosphate
[[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid
114661-04-0
p(nh)ppf
formycin a 5'-(beta-gamma-imido)triphosphate
SCHEMBL612075
DTXSID90180289
HY-130777
5'-o-[(s)-hydroxy{[(r)-hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl]adenosine
5'-adenylyl (|a,|a-imidodiphosphate)
128811-31-4
Q15989037
(2r)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-5-oxo-1-pyrrolidinecarboxylate-1,1-dimethylet
CS-0113351

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Here we demonstrate that extracellular ATP, ADP or AMPPNP caused synergistic enhancement of DNA synthesis in 3T6 mouse fibroblasts and BALB/MK keratinocytes when combined with any of the above polypeptides."( Extracellular ATP shows synergistic enhancement of DNA synthesis when combined with agents that are active in wound healing or as neurotransmitters.
Heppel, LA; Huang, NN; Wang, DJ, 1990
)
0.28
" We now show that phosphocreatine (PCr) in combination with hydrogen peroxide serves as an alternative phosphate donor and that ATP and PCr use distinct binding sites."( Phosphorylation of the insulin receptor kinase by phosphocreatine in combination with hydrogen peroxide: the structural basis of redox priming.
Dröge, W; Hacj, V; Hotz-Wagenblatt, A; Schmid, E, 1999
)
0.3

Bioavailability

ExcerptReferenceRelevance
" We hypothesized that inhibition of intestinal Pgp might decrease the efflux of etoposide from the blood into the intestinal lumen, thereby, increasing the bioavailability of etoposide."( Inhibition of intestinal P-glycoprotein and effects on etoposide absorption.
Huang, JD; Leu, BL, 1995
)
0.29
" Piperine is known to enhance the bioavailability of curcumin, as a substrate of P-gp by at least 2000%."( A plausible explanation for enhanced bioavailability of P-gp substrates in presence of piperine: simulation for next generation of P-gp inhibitors.
Godbole, MM; Misra, K; Singh, DV, 2013
)
0.39
"P-glycoprotein (Pgp) plays a pivotal role in drug bioavailability and multi-drug resistance development."( Drug-Induced Conformational Dynamics of P-Glycoprotein Underlies the Transport of Camptothecin Analogs.
Bartlett, MG; King, GM; Mensah, GAK; Roberts, AG; Schaefer, KG, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" To produce a dose-response curve for the effect of AMP-PNP on the rate of movement, the intracellular concentration of AMP-PNP in individual cells was measured."( Characterization of mitotic motors by their relative sensitivity to AMP-PNP.
Lee, GM, 1989
)
0.28
" The stimulatory effect of adenosine 5'-[beta,gamma-imido]triphosphate is the result of increasing the binding of insulin to the alpha subunit, and this reflects itself in a shift to the left of the insulin dose-response curve for autophosphorylation."( ATP sensitizes the insulin receptor to insulin.
Finn, FM; Hofmann, K; Ridge, KD, 1988
)
0.27
" When dose-response curves for the phosphodiesterase (PDE) inhibitor 3-isobutyl-1-methylxanthine (IBMX) were compared using perforated-patch vs."( Perforated-patch recording does not enhance effect of 3-isobutyl-1-methylxanthine on cardiac calcium current.
Kawamura, A; Wahler, GM, 1994
)
0.29
" ATP dose-response experiments, taken together with the effect of cAMP with and without ATP, suggest that phosphorylation is necessary, but not sufficient, for activation."( Regulation of CFTR Cl- conductance in secretion by cellular energy levels.
Bell, CL; Quinton, PM, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
adenosine 5'-phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Carbamoyl-phosphate SynthaseEscherichia coliKi400.0000400.0000400.0000400.0000AID977610
S-adenosylmethionine synthase isoform type-1Rattus norvegicus (Norway rat)Ki4.00004.00004.00004.0000AID107743
S-adenosylmethionine synthase isoform type-2Rattus norvegicus (Norway rat)Ki4.75004.00004.75005.5000AID107743; AID107901
Glycine--tRNA ligaseBombyx mori (domestic silkworm)Ki20.00000.80000.80000.8000AID1797699
Sensor protein kinase WalKStaphylococcus aureusIC50 (µMol)228.00007.18907.18907.1890AID1424768
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Potassium-transporting ATPase B chainEscherichia coliKd1,400.00001,400.00001,400.00001,400.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1199514Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as DQIIFMVGR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1424767Inhibition of Thermotoga maritima HK853 autophosphorylation using compound at non-aggregating concentration after 30 mins in presence of [gamma-33P]-ATP by phosphorescence-based assay2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Screening serine/threonine and tyrosine kinase inhibitors for histidine kinase inhibition.
AID1424768Inhibition of Streptococcus pneumoniae VicK autophosphorylation using compound at non-aggregating concentration after 30 mins in presence of [gamma-33P]-ATP by phosphorescence-based assay2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Screening serine/threonine and tyrosine kinase inhibitors for histidine kinase inhibition.
AID1199515Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as GYLSPDLSK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID523024Inhibition of aminoglycoside 3'-phosphotransferase 1B by PK/LDH-coupled assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Nucleotide selectivity of antibiotic kinases.
AID1272863Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged KIFC3 ATPase activity at 1 mM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1272861Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged Kif5B ATPase activity at 1 mM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1199507Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as WHGDVAVK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1272860Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged Eg5 ATPase activity at 1 mM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID107772Inhibitory potency against rat Methionine adenosyltransferase II1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID1272858Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged CENP-E ATPase activity at 1 mM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1199511Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as SIIHRDLK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID523011Inhibition of macrolide 2'-phosphotransferase 1 by PK/LDH-coupled assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Nucleotide selectivity of antibiotic kinases.
AID1199508Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as NEVGVLR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1199498Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as SPQKPIVR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1199512Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as SNNIFLHEDLTVK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1199516Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as SASEPSLNR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1199503Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as SIPIPQPFRPADEDHR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1199500Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as 7VVPAR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1199510Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as QTAQGMDYLHAK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1199513Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as IGDFGLATVK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1199505Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as DSSDDWEIPDGQITVGQR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1199504Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as GDGGSTTGLSATPPASLPGSLTNVK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1863316Inhibition of recombinant human RAD51/p53 (unknown origin) interaction at 200 uM measured by ELISA assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70Comparison of ATP-binding pockets and discovery of homologous recombination inhibitors.
AID107901Inhibitory constant against rat kidney Methionine adenosyltransferase II1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID1199506Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as IGSGSFGTVYK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1272864Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged MKLP1 ATPase activity at 1 mM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID227584Relative inhibitory potency T/II in rat methionine adenosyltransferase1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID1199502Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as DSLKK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1199499Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as VFLPNK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1272859Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged Kif4A ATPase activity at 1 mM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1614883Binding affinity to CK2alpha (unknown origin) at 500 uM by STD-based NMR spectroscopy2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.
AID107743Inhibitory constant against rat Methionine adenosyltransferase was reported1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID1199509Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as LIDIAR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1272862Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged KIF3C ATPase activity at 1 mM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1199517Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as TPIQAGGYGAFPVH accessible protease cleavage peptide level by LC-MS/MS analysis relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structural investigation of B-Raf paradox breaker and inducer inhibitors.
AID1413290Binding affinity to 1H/13C-Ile HSP90alpha CTD (unknown origin) at 2.5 mM by Methyl-TROSY 15N HSQC spectrum analysis2018MedChemComm, Aug-01, Volume: 9, Issue:8
Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain.
AID523023Inhibition of APH(3')-3a by PK/LDH-coupled assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Nucleotide selectivity of antibiotic kinases.
AID107588Inhibitory potency against rat Methionine adenosyltransferase was reported1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID1346599Human TRPM4 (Transient Receptor Potential channels)2004Pflugers Archiv : European journal of physiology, Apr, Volume: 448, Issue:1
Intracellular nucleotides and polyamines inhibit the Ca2+-activated cation channel TRPM4b.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2006The Journal of biological chemistry, Apr-07, Volume: 281, Issue:14
The holo-form of the nucleotide binding domain of the KdpFABC complex from Escherichia coli reveals a new binding mode.
AID1811Experimentally measured binding affinity data derived from PDB2006The Journal of biological chemistry, Apr-07, Volume: 281, Issue:14
The holo-form of the nucleotide binding domain of the KdpFABC complex from Escherichia coli reveals a new binding mode.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Flexibility in the ABC transporter MsbA: Alternating access with a twist.
AID1811Experimentally measured binding affinity data derived from PDB1999Biochemistry, Feb-23, Volume: 38, Issue:8
Carbamoyl phosphate synthetase: closure of the B-domain as a result of nucleotide binding.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1999Biochemistry, Feb-23, Volume: 38, Issue:8
Carbamoyl phosphate synthetase: closure of the B-domain as a result of nucleotide binding.
AID1797699In Vitro Enzyme Activity Assay from Article 10.1021/bi030031h: \\Thermodynamic characterization of the binding of nucleotides to glycyl-tRNA synthetase.\\2003Biochemistry, May-13, Volume: 42, Issue:18
Thermodynamic characterization of the binding of nucleotides to glycyl-tRNA synthetase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,102)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990356 (32.30)18.7374
1990's345 (31.31)18.2507
2000's254 (23.05)29.6817
2010's126 (11.43)24.3611
2020's21 (1.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.58 (24.57)
Research Supply Index7.02 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews13 (1.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other1,100 (98.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]